

Molecular Recognition

How to cite: *Angew. Chem. Int. Ed.* **2022**, *61*, e202210043

International Edition: doi.org/10.1002/anie.202210043

German Edition: doi.org/10.1002/ange.202210043

A 3D Peptide/[60]Fullerene Hybrid for Multivalent Recognition

Iván Gallego⁺, Javier Ramos-Soriano⁺, Alejandro Méndez-Ardoy, Justo Cabrera-González, Irene Lostalé-Seijo, Beatriz M. Illescas,^{*} Jose J. Reina,^{*} Nazario Martín,^{*} and Javier Montenegro^{*}

Dedicated to Professor Luis Echegoyen on occasion of his 70th birthday

Abstract: Fully substituted peptide/[60]fullerene hexakis-adducts offer an excellent opportunity for multivalent protein recognition. In contrast to monofunctionalized fullerene hybrids, peptide/[60]fullerene hexakis-adducts display multiple copies of a peptide in close spatial proximity and in the three dimensions of space. High affinity peptide binders for almost any target can be currently identified by in vitro evolution techniques, often providing synthetically simpler alternatives to natural ligands. However, despite the potential of peptide/[60]fullerene hexakis-adducts, these promising conjugates have not been reported to date. Here we present a synthetic strategy for the construction of 3D multivalent hybrids that are able to bind with high affinity the E-selectin. The here synthesized fully substituted peptide/[60]fullerene hybrids and their multivalent recognition of natural receptors constitute a proof of principle for their future application as functional biocompatible materials.

Introduction

The artificially engineered multivalent presentation of biomolecular ligands offers an excellent opportunity to improve both the binding affinities and the distribution and stability of protein binders and inhibitors.^[1–14] Among the different available platforms, the hexakis-adduct of [60]fullerene has shown great potential as a bio-compatible globular nanocarbon scaffold for three dimensional (3D) multivalent presentation of glycan ligands.^[15–17] Protein-glycan recognition events are behind critical biological processes including viral infection, cellular communication and metastatic development.^[18,19] Instead of highly selective enthalpic interactions, the specificity in this flow of chemical information emerges from entropic recognition events that

employ promiscuous multivalent binders. To achieve the required selectivity, Nature often capitalizes on chiral recognition by stereoselective multivalent glycan oligomers.^[20] One example is the interaction between sialylated oligosaccharides with proteins of the family of the selectins, which has been shown to be implicated in different key recognition mechanisms such as immune cell extravasation or tumor cell metastasis.^[18,21] However, the chemical synthesis of these saccharide ligands^[22] can be challenging and could delay the development of synthetic surrogates.^[23]

Monodisperse nanometric-sized platforms are emerging as hybrid systems for protein selective recognition.^[24,25] [60]Fullerene functionalization with T_h octahedral geometry can be efficiently achieved through direct Bingel-Hirsch cyclopropanation reaction by addition of suitably substituted

[*] Dr. I. Gallego,⁺ Dr. A. Méndez-Ardoy, Dr. I. Lostalé-Seijo, Dr. J. J. Reina, Dr. J. Montenegro
 Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela
 15705 Santiago de Compostela (Spain)
 E-mail: josejuan.reina@uma.es
 javier.montenegro@usc.es

Dr. J. Ramos-Soriano,⁺ Dr. J. Cabrera-González, Dr. B. M. Illescas, Prof. Dr. N. Martín
 Departamento de Química Orgánica, Facultad de Química, Universidad Complutense
 28040 Madrid (Spain)
 E-mail: beti@ucm.es
 nazmar@ucm.es

Prof. Dr. N. Martín
 IMDEA-Nanoscience
 C/ Faraday 9, Campus de Cantoblanco, 28049 Madrid (Spain)

Dr. J. J. Reina
 Present address: Universidad de Málaga, IBIMA, Dpto. de Química Orgánica
 Campus de Teatinos, s/n. 29071 Málaga (Spain)
 and
 Centro Andaluz de Nanomedicina y Biotecnología, BIONAND, Parque Tecnológico de Andalucía, C/Severo Ochoa, 35, 29590 Campanillas (Málaga) (Spain)

Dr. J. Ramos-Soriano⁺
 Present address: Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), CSIC, Universidad de Sevilla
 Av. Américo Vespucio, 49, 41092 Seville (Spain)

[†] These authors contributed equally to this work.

© 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

malonates.^[26] This procedure allows the preparation of a [60]fullerene hexakis-adduct appended with 12 alkyne moieties, whose further regioselective modification can be efficiently carried out by copper-catalyzed alkyne-azide cycloaddition (CuAAC).^[27]

Furthermore, the introduction of a copper-free strain-promoted alkyne-azide cycloaddition (SPAAC)^[28–30] strategy overcomes the copper-related limitations for biological applications.^[31] A recent modified version of SPAAC, under mild microwave irradiation (MW) conditions (50 °C), allows the very efficient fullerene functionalization in short times (30 min) to afford highly substituted biocompatible hybrid systems (e.g., glycofullerenes).^[32] Stepwise synthesis of [5:1]-hexa-adducts of [60]fullerene and further development in orthogonal click additions have allowed the asymmetric substitution of A₁₀B [60]fullerenes to combine multivalent ligands together with probes or therapeutics agents.^[33,34] Over the last years, this multistep synthesis of functionalized fullerenes has shown great potential for blocking the carbohydrate recognition domain of the receptor for different emerging viruses such as Ebola,^[35,36] Zika,^[33] and Dengue.^[33]

Recent advances in the screening and *in vitro* optimization of potential selective binders based on nucleic acids, peptides, and antibody or antibody mimetics^[37] constitute a highly promising new scenario for the fullerene multivalent presentation of biomolecular scaffolds. For example, the use of the systematic evolution of ligands by exponential enrichment technology (SELEX)^[38] for nucleic acids, or display platforms (phage display, yeast display, ribosome display and so on)^[37,39–41] for peptides and proteins currently allow the directed evolution of high affinity binders for almost any conceivable target. In this regard, the possible coupling of the fullerene scaffold with peptide binders, developed by phage display optimization (Nobel prize 2018),^[40,42] will offer a unique opportunity for the design of universal nanoplat-forms for selective protein receptor recognition. However, despite the strong potential of this strategy,^[43,44] the multi-step, complete functionalization of the fullerene scaffold by defined peptide oligomers has not yet been experimentally achieved.

In this paper, we describe the first synthesis of a fully substituted peptide/[60]fullerene hexakis-adduct by combining solid phase peptide synthesis and fullerene click chemistry. In contrast to previously reported fullerenes monofunctionalized or randomly derivatized with peptides or protein pendants,^[45–53] this work constitutes the first example of a fully substituted fullerene/peptide hybrid hexakis-adduct for multivalent protein recognition. The results reported here confirm the potential of the [60]fullerene for the multivalent presentation of robust and easily accessible peptide ligands as a viable alternative to natural ligands (Figure 1). The here described synthetic pathway and optimized reaction conditions, based on hexakis-adducts of [60]fullerene appended with cyclooctynes for SPAAC, allowed the obtention of well-defined mono-disperse fullerene/peptide hybrids in quantitative yield by using mild conditions, and avoiding additional purification steps.




Figure 1. Different steps in the molecular scaffold construction: a) *In vitro* identification of a mimetic (IELLQAR) of a natural ligand (sLe^x); b) Development of a highly substituted peptide/[60]fullerene hybrid; c) Multivalent and selective recognition of E-selectin (dark-teal receptors) by the fullerene hybrids, with the potential application of blocking the attachment of sLe^x-overexpressing circulating tumor cells (gray cells) to the activated endothelium (pink cells) with the subsequent inhibition of metastasis.

A selective peptide binder, previously identified by phage display to target the lectin binding domain of the E-selectin,^[54] was employed to achieve the experimental proof of principle of fullerene-mediated peptide multivalent presentation and selective protein recognition. E-selectin is a well known receptor with multivalent ligands that is involved in cancer cell trafficking and that can be potentially used as a target for diagnosis and treatment.^[18,21,55] Therefore, it constitutes an optimal receptor for this study. The [60]fullerene hexakis-adduct was equipped with twelve peptide subunits that were specifically recognized by the protein receptor (Figure 1). The surface plasmon resonance (SPR) binding characterization confirmed the importance of the peptide to fullerene linker orientation for the suitable presentation of chemical information on the globular carbon template. Asymmetric A₁₀B [60]fullerenes fluorescently labelled at the focal point with a Rhodamine probe were also synthesized and employed to study the specific recognition of the E-selectin surface receptors in the membrane of endothelial cells.

Results and Discussion

Design, synthesis and SPR studies of peptide ligands

Selectin adhesion receptors were chosen as excellent candidates for peptide/[60]fullerene multivalent specific recognition. Although the sialylated oligosaccharides sialyl Lewis X (sLe^X) and its isomer sialyl Lewis A (sLe^A) are the natural ligands of selectins, their weak binding constant (in the low mM range)^[54] can be improved by their protein or lipid-supported multivalent presentation.^[14,54,56]

Nevertheless, the overexpression of the E-selectin receptors at the surface of cytokine activated vascular endothelium,^[57] a potential receptor site for circulating tumor cells, makes the synthesis of such inhibitors a primary target, which has been mainly approached by antibodies, thio-aptamers, and non-natural saccharides.^[55] Phage display in vitro directed evolution has allowed the identification of a simple linear peptide sequence (IELLQAR) that interacts specifically with selectins, with an order of magnitude higher affinity than sLe^X, and that can be employed to inhibit sLe^X-dependent metastasis.^[54,58]

Therefore, we hypothesized that the quantitative coupling of this peptide to the hexakis-adduct of the fullerene core would afford a biocompatible globular scaffold for the 3D presentation of multiple peptide copies for protein recognition (Figure 2). It should be noted that this peptide was simply selected as an excellent example to demonstrate the potential functional capacities of fully substituted peptide fullerene adducts.

To synthesize IELLQAR peptide/[60]fullerene adducts, the peptide must be conjugated to the multivalent platform. To determine the influence of the linker in the binding affinity of the IELLQAR peptide to the E-selectin, we considered a head or tail peptide connection by anchoring to the fullerene either: i) the free amino group of the isoleucine residue located at the peptide N-terminus, or ii) an amino group located on an additional new lysine residue introduced at the peptide C-terminus (Figure 3). The linker connector was based on a short hydrophilic tetraethylene-glycol moiety equipped with two orthogonal functionalization sites: a carboxylic acid and a terminal azido group (**1**). This compound allowed both the conjugation to the peptide by amide bond formation and the subsequent attachment to




Figure 2. Synthetic analysis of these peptide/[60]fullerene platforms. SPAAC reaction between peptides modified with an azide group: the IELLQARK (active peptide) and ISELRSE (negative control peptide) and the cyclooctyne groups of C₆₀ fullerene hexakis-adducts to give rise to the symmetric hybrids: the active F₁ (C₆₀-(IELLQARK)₁₂) and the control F_C (C₆₀-(ISELRSE)₁₂), as well as the asymmetric Rhodamine B fullerene adducts: the active F₁^{RB} (RB-C₆₀-(IELLQARK)₁₀) and control F_C^{RB} (RB-C₆₀-(ISELRSE)₁₀).




Figure 3. Peptide IELLQAR-(PEG)₄-N₃ (**P**₁) was prepared by adding a new lysine amino acid previously modified with the corresponding oligoethylene glycol linker (**2**) at the C-terminus in the beginning of the synthesis. Peptide N₃-(PEG)₄-IELLQAR (**P**₂) was prepared by incorporating the polyethylene glycol linker (**1**) at the N-terminus at the end of the solid phase synthesis (see section 3 in the Supporting Information).

the [60]fullerene cyclooctyne adduct via SPAAC click reaction. Two different peptide sequences were firstly synthesized by Fmoc solid-phase, namely: IELLQAR-(PEG)₄-N₃ (**P**₁) and N₃-(PEG)₄-IELLQAR (**P**₂) (Figures 3, S6 and S7). For the synthesis of the N-terminus functionalized **P**₂, the polyethylene glycol linker (**1**) was conjugated in the last step of the solid phase synthesis strategy (Figures 3 and S7). To prepare the C-terminus functionalized peptide **P**₁, it was necessary to use a new lysine amino acid, previously modified with the corresponding oligoethylene glycol linker (**2**). This customized lysine (**2**) was anchored to the resin as first amino acid derivative during the solid phase synthesis of **P**₁ (Figures 3 and S6). After HPLC purification, the final oligoethyleneglycol modified peptides (**P**₁ and **P**₂) showed an excellent purity and water solubility.

To determine which one of the two different anchoring sites of the IELLQAR peptide (N- or C-terminal linkers) would afford the optimal presentation geometry, we sought to initially study the interaction of these monovalent peptides (**P**₁ and **P**₂) with the E-selectin protein by surface plasmon resonance (SPR) direct binding experiments (see Supporting Information, section 6).

Binding data were collected at a flow rate of 30 μL min⁻¹ at increasing concentrations of the peptides **P**₁, and **P**₂, and the sLe^x pentasaccharide natural ligand (Figure S40). Prior to analysis, binding tests with E-selectin at different flow rates were performed to discard mass transport effects that could influence the sensorgrams shape. The SPR sensorgrams obtained were fit to a Langmuir 1:1 binding mode, and the kinetic and binding constants (k_{on} (k_a), k_{off} (k_d)) were calculated by dose-response experiments on the E-

selectin surface (Figure S40). Kinetic evaluation of the resulting curves was performed, and a dissociation constant (K_D) value was obtained for the two peptides **P**₁, **P**₂, and sLe^x (Table 1).

The C-terminus modified peptide **P**₁ showed the best binding affinity to the E-selectin receptor with a K_D of 5.16×10^{-5} M, which was almost one order of magnitude lower than that of the natural ligand sLe^x ($K_D = 1.75 \times 10^{-4}$ M). In contrast, the N-terminus modified peptide **P**₂ showed a significant drop in the affinity for the E-selectin receptor ($K_D = 2.95 \times 10^{-3}$ M), which confirmed that the attachment orientation of peptide to the fullerene scaffold can significantly interfere with the peptide binding to the E-selectin. Therefore, these results remark that for hexakis-adducts of [60]fullerene with peptides, the linkers should be independently optimized for each particular peptide, and also confirmed the C-terminus functionalized peptide **P**₁ as the best candidate for further development of this peptide/[60]fullerene hybrid system.

Synthesis of Chemically Modified [60]Fullerenes

The synthetic route to obtain symmetric hexakis-adduct **F**₁ decorated with twelve peptides **P**₁ is depicted in Figure 4. The previous phage display optimization indicated that similar peptides to that of the hit peptide sequence (IELLQAR) could retain certain binding activity.^[54] Therefore, a negative control peptide, **P**_C, was designed with a random hydrophilic sequence to prevent it from affecting the solubility of the macromolecules and from interacting

Table 1: Kinetic constants determined by SPR.

	k_a [1/M s] ^[a]	k_d [1/s] ^[a]	$K_D = k_d/k_a$ [M] ^[a]
sLe ^x	5.34×10^6	9.33×10^2	1.75×10^{-4}
P ₁	44.8 ± 2.14	$2.31 \times 10^{-3} \pm 4.91 \times 10^{-4}$	$5.16 \times 10^{-5} \pm 1.22 \times 10^{-6}$
P ₂	26.4 ± 2.45	$7.79 \times 10^{-2} \pm 3.81 \times 10^{-3}$	$2.95 \times 10^{-3} \pm 1.97 \times 10^{-4}$
F ₁	$1.01 \times 10^4 \pm 1.87 \times 10^3$	$5.85 \times 10^{-4} \pm 1.84 \times 10^{-4}$	$6.04 \times 10^{-8} \pm 2.65 \times 10^{-8}$
F ₁ ^{RB}	$1.37 \times 10^4 \pm 6.28 \times 10^3$	$3.34 \times 10^{-3} \pm 1.89 \times 10^{-3}$	$2.54 \times 10^{-7} \pm 1.06 \times 10^{-7}$

[a] The kinetic constants obtained correspond to the average of the kinetic constants for each of the concentrations for sLe^x, **P**₁, **P**₂, **F**₁ and **F**₁^{RB}.




Figure 5. Synthesis of labeled peptide/[60]fullerenes F_1^{RB} and F_C^{RB} . Reagents and conditions: i) NaN₃, DMF, 60 °C, 3 days (quant.); ii) EDC-HCl, DMAP, CH₂Cl₂/DMF, r.t., overnight (quant.); iii) **6** (1 equiv), **8** (2 equiv), DMSO, MW 50 °C, 30 min (99%); iv) **9** (1 equiv), **10** (15 equiv), DCC, DPTS, CH₂Cl₂/DMF, r.t., overnight (99%); v) **11** (1 equiv), P₁ or P_C (10 equiv), DMSO, MW 50 °C, 30 min (for F_1^{RB} from P₁, 99%, and for F_C^{RB} from P_C, quant.).

compounds F_1 , F_C , F_1^{RB} and F_C^{RB} were difficult to obtain, and the molecular ion peak could not be observed due to the very high molecular mass of the compounds and high level of fragmentation. Therefore, XPS analysis was additionally employed to confirm the elemental composition of the final peptide/[60]fullerenes (see section 4 in the Supporting Information). The registered full scanned spectra give us information about the atoms present in their molecular structure. As expected, contributions steaming from the core levels of C 1s (284.6 eV), N 1s (398.6 eV), and O 1s (531.6 eV), were the only elements present in the analysis. Their relative abundances are collected in Table 2 and are in agreement with the theoretical calculated values for each compound. The S 2p doublet (S 2p^{1/2} and S 2p^{3/2}) for the labeled peptide fullerenes F_1^{RB} and F_C^{RB} feature is missing in the survey spectra due to the low resolution of XPS for

this atom and its low atomic presence in the molecule. Moreover, the chemical state of C 1s and N 1s has been analysed in a high-resolution spectrum. The C 1s was deconvoluted into three symmetrical (Gaussian-Lorentzian curves) major components corresponding to C=C/C-C at 283.9 eV, C-O/C-N at 285.2 eV and N-C=O/C=O/O-C=O/C=N at 287.0 eV, presenting similar behaviour in all compounds (Figures S17b, S20b, S35b, and S38b). Analysing the N 1s peak decomposition, we observed three main components, as depicted in Figures S17c, S20c, S35c, and S38c. One major peak was observed at around 399.0 eV, assigned to the amide groups (N-C=O) characteristic of the peptide chain. The C-N peak was found at lower binding energies (398.3 eV) and is assigned, among others, to the two N atoms bound to C of the triazole ring. Finally, the third and minor component ($\approx 7\%$) with binding energy of

Table 2: Relative abundances of C, N and O determined by XPS for peptide/[60]fullerenes F_1 , F_C , F_1^{RB} and F_C^{RB} .

	Atomic percentage [%] ^[a]			Molecular formula
	C	N	O	
F_1	65.8 (66.0)	13.7 (14.1)	20.5 (19.9)	$C_{954}H_{1536}N_{204}O_{288}$
F_C	64.3 (63.8)	12.1 (12.7)	23.5 (23.5)	$C_{846}H_{1308}N_{168}O_{312}$
F_1^{RB}	67.2 (66.8)	13.1 (13.5)	19.8 (19.7)	$C_{869}H_{1365}N_{175}O_{256}S$
F_C^{RB}	64.2 (64.9)	11.8 (12.1)	23.9 (23.0)	$C_{779}H_{1175}N_{145}O_{276}S$

[a] Theoretical values are given in brackets.

near 400 eV belong to the third nitrogen of the triazole ring N–N–N. Note that, in all the analysed samples, no azido group peak (≈ 405.0 eV) is observable, confirming the lack of unbound organic molecule and the quantitative formation of the triazole ring.

Analysis of F_1 in solution by dynamic light scattering (DLS) showed two size populations (≈ 8 nm and 200 nm) depending on the aqueous buffer employed (Figure S39a). Scanning transmission electron microscopy (STEM) and atomic force microscopy (AFM) also revealed size distributions (8, 25 nm) consistent with the size of individual and small assemblies of the peptide fullerene hybrid macromolecules (Figure S39b and S39c).

Surface Plasmon Resonance Binding Assays

SPR biosensor direct binding assays were performed to compare the binding of the different peptide/[60]fullerene conjugates to E-selectin. A high capacity sensorchip was functionalized with E-selectin following the same procedure as previously described, and binding data were collected at a flow rate of $30 \mu\text{L min}^{-1}$ at increasing fullerene concentrations (see Supporting Information, section 6). As expected, the more complex binding profiles of the sensorgrams suggested a multivalent nature for the binding of the peptide/[60]fullerene hybrids to the chip supported protein (Figure 6 and Figure S41). As previously described in the literature,^[59,60] a separate kinetic analysis of guest multivalent binding was carried out at diluted concentrations for the initial association and late dissociation binding events. The sensorgrams of the binding peptide/[60]fullerene conjugates (F_1 and F_1^{RB}) showed a two-phase dissociation process ($t > 240$ s), which consisted in an initial fast dissociation phase followed by an extremely slow dissociation phase. A higher degree of heterogeneity in the binding events was also found at early dissociation times ($t = 240\text{--}360$ s, Figure 6), but late dissociation times ($t > 600$ s) showed a good fitting to a 1:1 Langmuir binding model. Kinetic evaluation of the early binding region ($t < 50$ s) showed a linear dependence during the association phase, which could also be fitted to a 1:1 Langmuir binding model (Figure S41). The kinetic profile of the sensorgrams at short times showed a fast association at low concentrations ($< 12.5 \mu\text{M}$) that was reduced at higher ligand concentrations, which was consistent with a multivalent binding of the peptide/[60]fullerene hybrid system.




Figure 6. SPR sensorgrams of hybrid fullerenes a) F_1 , and b) F_1^{RB} at (12.5–0.78) μM binding to E-selectin functionalized surfaces (representative graphics for low density (LD) functionalization, see Supporting Information). The association times below 50 s (yellow lines) and dissociation times longer than 600 s (red lines) used for constant determination (Table 1, Supporting Information) are shown.

The analysis of the SPR curves showed that the conjugate F_1 , with twelve peptide units at the fullerene surface, binds E-selectin with a dissociation constant in the nanomolar range ($K_D = 6.04 \times 10^{-8}$ M), indicating a multivalent effect resulting in an affinity enhancement (β) factor of 71 (see section 6 in the Supporting Information).^[61] The affinity of this binding peptide/[60]fullerene conjugate F_1 increases up to 3 orders of magnitude relative to its monomeric counterpart, which validates the functional capacity of the [60]fullerene hexakis-adduct to display multiple copies of a peptide ligand and establish multivalent interactions with the corresponding suitable protein receptor (Figure 6). Despite multivalent interactions were also observed for the fluorescent asymmetric fullerene, a decrease in the binding constant ($K_D = 2.54 \times 10^{-7}$ M) was obtained for F_1^{RB} , where two peptide copies have been substituted by a rhodamine fluorescence probe (Figures 5, 6 and S41). As expected, control experiments with the non-specific hydrophilic peptide modified fullerenes F_C and F_C^{RB} showed no apparent binding to the E-selectin receptor (Figure S42).

Cellular Studies

After the synthesis and the SPR binding studies to the E-selectin, in vitro cell studies were carried out to confirm the potential capacity of the new peptide/[60]fullerene conju-

gates F_1^{RB} and F_C^{RB} to recognize surface receptors in living cells. The human umbilical vein endothelial cell line (HUVEC) was selected as a model for human endothelial cells expressing the E-selectin.^[62] This cell line can be activated by tumor necrosis factor alpha (TNF α) that induces the overexpression of membrane adhesion molecules such as the E-selectin (Figure S43). As confirmed by SPR, the specific E-selectin binding of the fluorescent adduct F_1^{RB} was in a suitable concentration range for potential *in vitro* cell binding assays. Therefore, the potential selective cellular adhesion of the fluorescent targetable adduct F_1^{RB} versus the negative control fullerene F_C^{RB} were both tested with activated and non-activated HUVEC cells (Figure 7).

Two sets of HUVEC cells were cultured in parallel, in the presence or in the absence of TNF α , to induce E-selectin overexpression in one of the groups. Both groups of HUVECs were then incubated with the fluorescently labelled binding F_1^{RB} and the control F_C^{RB}

peptide/[60]fullerene conjugates for 30 min (see Supporting Information, section 7). The cells were thoroughly washed with heparin and HKR buffer to remove any potential excess of fullerene adducts and were then observed by live-cell confocal microscopy (Figure 7). The resulting micrographs confirmed an excellent selectivity of the interaction of the F_1^{RB} conjugate towards the TNF α treated HUVEC cells (Figure 7). Residual fluorescence was observed in non-treated HUVEC cells that did not express the E-selectin receptor. The corresponding control experiments with the control F_C^{RB} fullerene conjugate showed residual fluorescence in both untreated and TNF α treated HUVEC cells, which confirmed the selectivity of the cellular binding process. Flow cytometry quantification validated the selectivity of the peptide/[60]fullerene adhesion (Figure 7).

Conclusion

The objective of this study was to synthesize and experimentally demonstrate the potential of a fully substituted peptide/[60]fullerene conjugate for the 3D multivalent presentation of the chemical information of peptide oligomers for protein recognition. This proof of principle is secured by a detailed collection of spectroscopic characterization of the conjugates and the corresponding E-selectin binding experiments in model surfaces and living cells. In this work, solid phase peptide synthesis and a copper-free SPAAC click chemistry approach were combined for the efficient preparation of highly substituted peptide/[60]fullerene conjugates. The globular structure of the resulting [60]fullerene hexakis-adducts allowed the maximum spacing between the twelve IELLQAR copies in a minimal multivalent nanoplat-form for protein recognition. Surface plasmon resonance unambiguously confirmed the multivalent specific E-selectin binding, which was also validated in living cells models. These results support the potential of fullerene conjugates for the multivalent presentation of peptide ligands with specific information for protein recognition.

The here described peptide/[60]fullerene conjugates constitute an original new strategy for multivalent recognition that for the first time exploits the synthetic simplicity, the stability and the versatility of peptide binders supported on fully substituted fullerene templates. We hope that this report will pave the way for the synthesis of a new range of promising fully substituted peptide/fullerene hybrid materials with potential applications in protein targeting and biomedical sciences.

Acknowledgements

This work was partially supported by the Spanish Agencia Estatal de Investigación (AEI) [SAF2017-89890-R, PCI2019-103400, PID2020-117143RB-I00, PID2020-114653RB-I00 and PID2020-115120GB-I00], Xunta de Galicia (ED431C 2017/25 and Centro singular de investigación de Galicia accreditation 2019–2022, ED431G 2019/03) and the European Commission (EC) (European Regional




Figure 7. Cellular assay. a) Confocal microscopy images of HUVEC cells (top row) or TNF α -treated HUVEC cells (bottom row) incubated with 10 μ M of F_1^{RB} (left column) or F_C^{RB} (right column). Scale bar: 25 μ m. b) Flow cytometry assay of HUVEC cells incubated with 10 μ M of F_1^{RB} or F_C^{RB} , pretreated (gray checkered bars) or not (smooth gray bars) with 10 ng mL $^{-1}$ of TNF α . Data presented as mean of the median fluorescence intensity of three replicates \pm standard deviation.

Development Fund-ERDF). J.M. thanks the ERC-STG (DYNAP, 677786), ERC-POC (TraffikGene, 838002), Xunta de Galicia (Oportunus Program) and Human Frontier Science Programme Young Investigator Grant (RGY0066/2017) for funding. J.J.R. received a Beatriz Galindo Grant (BEAGAL18-00051) by the Spanish Ministerio de Universidades. I.G. received predoctoral fellowships (ED481A-2018/116 and FPU17/00941). J.C.-G. thanks the Comunidad de Madrid Atracción de Talento program (2018-T2/BMD-10275). Figures created with BioRender.com.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords: Fullerenes · Glycomimetic · Lectin · Multivalency · Peptides

- [1] D. Lauster, S. Klenk, K. Ludwig, S. Nojoui, S. Behren, L. Adam, M. Stadtmüller, S. Saenger, S. Zimmler, K. Hönzke, et al., *Nat. Nanotechnol.* **2020**, *15*, 373–379.
- [2] I. Gallego, A. Rioboo, J. J. Reina, B. Díaz, Á. Canales, F. J. Cañada, J. Guerra-Varela, L. Sánchez, J. Montenegro, *Chem-BioChem* **2019**, *20*, 1400–1409.
- [3] M. Juanes, I. Lostalé-Seijo, J. R. Granja, J. Montenegro, *Chem. Eur. J.* **2018**, *24*, 10689–10698.
- [4] S. J. Kwon, D. H. Na, J. H. Kwak, M. Douaisi, F. Zhang, E. J. Park, J. H. Park, H. Youn, C. S. Song, R. S. Kane, et al., *Nat. Nanotechnol.* **2017**, *12*, 48–54.
- [5] F. J. Martínez-Veracochea, D. Frenkel, *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 10963–10968.
- [6] Y. Xiang, S. Nambulli, Z. Xiao, H. Liu, Z. Sang, W. P. Duprex, D. Schneidman-Duhovny, C. Zhang, Y. Shi, *Science* **2020**, *370*, 1479–1484.
- [7] D. Budhadev, E. Poole, I. Nehlmeier, Y. Liu, J. Hooper, E. Kalverda, U. S. Akshath, N. Hondow, W. B. Turnbull, S. Pöhlmann, et al., *J. Am. Chem. Soc.* **2020**, *142*, 18022–18034.
- [8] E. Blattes, A. Vercellone, H. Eutamene, C.-O. Turrin, V. Theodorou, J.-P. Majoral, A.-M. Caminade, J. Prandi, J. Nigou, G. Puzo, *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 8795–8800.
- [9] S.-J. Richards, M. I. Gibson, *JACS Au* **2021**, *1*, 2089–2099.
- [10] A. N. Zelikin, F. Stellacci, *Adv. Healthcare Mater.* **2021**, *10*, 2001433.
- [11] I. Insua, J. Montenegro, *Chem* **2020**, *6*, 1652–1682.
- [12] N. Kanfar, E. Bartolami, R. Zelli, A. Marra, J.-Y. Winum, S. Ulrich, P. Dumy, *Org. Biomol. Chem.* **2015**, *13*, 9894–9906.
- [13] E. A. Perets, A. S. D. S. Indrasekara, A. Kurmis, N. Atlasevich, L. Fabris, J. Arslanoglu, *Analyst* **2015**, *140*, 5971–5980.
- [14] C. Fasting, C. A. Schalley, M. Weber, O. Seitz, S. Hecht, B. Kokschi, J. Dervede, C. Graf, E.-W. Knapp, R. Haag, *Angew. Chem. Int. Ed.* **2012**, *51*, 10472–10498; *Angew. Chem.* **2012**, *124*, 10622–10650.
- [15] B. M. Illescas, J. Rojo, R. Delgado, N. Martín, *J. Am. Chem. Soc.* **2017**, *139*, 6018–6025.
- [16] J.-F. Nierengarten, *Chem. Commun.* **2017**, *53*, 11855–11868.
- [17] E. Castro, A. H. Garcia, G. Zavala, L. Echegoyen, *J. Mater. Chem. B* **2017**, *5*, 6523–6535.
- [18] B. A. H. Smith, C. R. Bertozzi, *Nat. Rev. Drug Discovery* **2021**, *20*, 217–243.
- [19] A. C. Mendes, E. T. Baran, R. L. Reis, H. S. Azevedo, *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2013**, *5*, 582–612.
- [20] R. A. Laine, *Glycobiology* **1994**, *4*, 759–767.
- [21] U. Harjes, *Nat. Rev. Cancer* **2019**, *19*, 301–301.
- [22] J. J. Reina, A. Rioboo, J. Montenegro, *Synthesis* **2018**, *50*, 831–845.
- [23] K. Ley, *Trends Mol. Med.* **2003**, *9*, 263–268.
- [24] J. Ramos-Soriano, J. Rojo, *Chem. Commun.* **2021**, *57*, 5111–5126.
- [25] J. L. Jiménez Blanco, J. M. Benito, C. Ortiz Mellet, J. M. García Fernández, *J. Drug Delivery Sci. Technol.* **2017**, *42*, 18–37.
- [26] A. Hirsch, in *Fullerenes Relat. Struct.* (Ed.: A. Hirsch), Springer, Berlin, Heidelberg, **1999**, pp. 1–65.
- [27] I. Nierengarten, J.-F. Nierengarten, *Chem. Rec.* **2015**, *15*, 31–51.
- [28] N. J. Agard, J. A. Prescher, C. R. Bertozzi, *J. Am. Chem. Soc.* **2004**, *126*, 15046–15047.
- [29] N. J. Agard, J. M. Baskin, J. A. Prescher, A. Lo, C. R. Bertozzi, *ACS Chem. Biol.* **2006**, *1*, 644–648.
- [30] J. M. Baskin, J. A. Prescher, S. T. Laughlin, N. J. Agard, P. V. Chang, I. A. Miller, A. Lo, J. A. Codelli, C. R. Bertozzi, *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 16793–16797.
- [31] C. Ornelas, J. Broichhagen, M. Weck, *J. Am. Chem. Soc.* **2010**, *132*, 3923–3931.
- [32] J. Ramos-Soriano, J. J. Reina, A. Pérez-Sánchez, B. M. Illescas, J. Rojo, N. Martín, *Chem. Commun.* **2016**, *52*, 10544–10546.
- [33] J. Ramos-Soriano, J. J. Reina, B. M. Illescas, N. de la Cruz, L. Rodríguez-Pérez, F. Lasala, J. Rojo, R. Delgado, N. Martín, *J. Am. Chem. Soc.* **2019**, *141*, 15403–15412.
- [34] J. Ramos-Soriano, J. J. Reina, B. M. Illescas, J. Rojo, N. Martín, *J. Org. Chem.* **2018**, *83*, 1727–1736.
- [35] L. Rodríguez-Pérez, J. Ramos-Soriano, A. Pérez-Sánchez, B. M. Illescas, A. Muñoz, J. Luczkowiak, F. Lasala, J. Rojo, R. Delgado, N. Martín, *J. Am. Chem. Soc.* **2018**, *140*, 9891–9898.
- [36] A. Muñoz, D. Sigwalt, B. M. Illescas, J. Luczkowiak, L. Rodríguez-Pérez, I. Nierengarten, M. Holler, J.-S. Remy, K. Buffet, S. P. Vincent, et al., *Nat. Chem.* **2016**, *8*, 50–57.
- [37] R. Simeon, Z. Chen, *Protein Cell* **2018**, *9*, 3–14.
- [38] M. Darmostuk, S. Rimpelova, H. Gbelcova, T. Ruml, *Biotechnol. Adv.* **2015**, *33*, 1141–1161.
- [39] C. G. Ullman, L. Frigotto, R. N. Cooley, *Briefings Funct. Genomics Proteomics* **2011**, *10*, 125–134.
- [40] G. P. Smith, V. A. Petrenko, *Chem. Rev.* **1997**, *97*, 391–410.
- [41] A. Sergeeva, M. G. Kolonin, J. J. Molldrem, R. Pasqualini, W. Arap, *Adv. Drug Delivery Rev.* **2006**, *58*, 1622–1654.
- [42] S. Mimmi, D. Maisano, I. Quinto, E. Iaccino, *Trends Pharmacol. Sci.* **2019**, *40*, 87–91.
- [43] M. Ruiz-Santaquiteria, B. M. Illescas, R. Abdelnabi, A. Boonen, A. Mills, O. Martí-Marí, S. Noppen, J. Neyts, D. Schols, F. Gago, et al., *Chem. Eur. J.* **2021**, *27*, 10700–10710.
- [44] H. Li, B. Zhang, X. Lu, X. Tan, F. Jia, Y. Xiao, Z. Cheng, Y. Li, D. O. Silva, H. S. Schrekker, et al., *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 4340–4344.
- [45] A. Svitova, K. Braun, A. A. Popov, L. Dunsch, *ChemistryOpen* **2012**, *1*, 207–210.
- [46] H. L. Fillmore, M. D. Shultz, S. C. Henderson, P. Cooper, W. C. Broaddus, Z. J. Chen, C.-Y. Shu, J. Zhang, J. Ge, H. C. Dorn, et al., *Nanomedicine* **2011**, *6*, 449–458.
- [47] J. Shi, B. Wang, L. Wang, T. Lu, Y. Fu, H. Zhang, Z. Zhang, *J. Controlled Release* **2016**, *235*, 245–258.
- [48] L. Tanzi, M. Terreni, Y. Zhang, *Eur. J. Med. Chem.* **2022**, *230*, 114104.

- [49] S. Bosi, T. Da Ros, G. Spalluto, M. Prato, *Eur. J. Med. Chem.* **2003**, *38*, 913–923.
- [50] D. M. Rivera-Nazario, J. R. Pinzón, S. Stevenson, L. A. Echegoyen, *J. Phys. Org. Chem.* **2013**, *26*, 194–205.
- [51] A. R. Barron, *J. Enzyme Inhib. Med. Chem.* **2016**, *31*, 164–176.
- [52] S. Jennepalli, S. G. Pyne, P. A. Keller, *RSC Adv.* **2014**, *4*, 46383–46398.
- [53] D. Pantarotto, A. Bianco, F. Pellarini, A. Tossi, A. Giangaspero, I. Zelezetsky, J.-P. Briand, M. Prato, *J. Am. Chem. Soc.* **2002**, *124*, 12543–12549.
- [54] M. N. Fukuda, C. Ohyama, K. Lowitz, O. Matsuo, R. Pasqualini, E. Ruoslahti, M. Fukuda, *Cancer Res.* **2000**, *60*, 450–456.
- [55] E. Jubeli, L. Moine, J. Vergnaud-Gauduchon, G. Barratt, *J. Controlled Release* **2012**, *158*, 194–206.
- [56] S. Gout, P.-L. Tremblay, J. Huot, *Clin. Exp. Metastasis* **2008**, *25*, 335–344.
- [57] M. Bevilacqua, S. Stengelin, M. Gimbrone, B. Seed, *Science* **1989**, *243*, 1160–1165.
- [58] J. Zhang, J. Nakayama, C. Ohyama, M. Suzuki, A. Suzuki, M. Fukuda, M. N. Fukuda, *Cancer Res.* **2002**, *62*, 4194–4198.
- [59] E. M. Munoz, J. Correa, R. Riguera, E. Fernandez-Megia, *J. Am. Chem. Soc.* **2013**, *135*, 5966–5969.
- [60] M. Salvadó, J. J. Reina, J. Rojo, S. Castellón, O. Boutureira, *Chem. Eur. J.* **2017**, *23*, 15790–15794.
- [61] V. M. Krishnamurthy, L. A. Estroff, G. M. Whitesides, *Fragment-based Approaches in Drug Discovery*, Wiley-VCH, Weinheim, **2006**, pp. 11–53.
- [62] M. H. Thornhill, J. Li, D. O. Haskard, *Scand. J. Immunol.* **1993**, *38*, 279–286.

Manuscript received: July 8, 2022

Accepted manuscript online: August 21, 2022

Version of record online: September 6, 2022